Literature DB >> 18630504

Interferon-alpha restitutes the chemosensitivity in pancreatic cancer.

Katrin Hoffmann1, Stefan Mehrle, Jan Schmidt, Markus W Büchler, Angela Märten.   

Abstract

BACKGROUND: Multidrug resistance is a major obstacle in the treatment of pancreatic cancer. Immunochemotherapy including interferon-alpha increases response rates and survival.
MATERIALS AND METHODS: Pancreatic cancer was induced in an orthotopic mouse model. Animals received standard chemotherapy or combinative treatment with interferon-alpha. Expression and function of drug-resistance proteins were analyzed. Immunological phenotyping, cytotoxic activity assays and analysis of T-cell activation status were performed.
RESULTS: Addition of interferon-alpha to chemotherapeutic regimes significantly reduced chemotherapy-induced expression of multidrug resistance proteins and drug efflux activity of cancer cells. Tumor size and metastatic seeding decreased significantly upon combination therapy and survival was prolonged. A significantly higher proportion of activated and cytotoxic active CD8+ tumor infiltrating lymphocytes was detectable after induction of drug resistance.
CONCLUSION: Restitution of chemosensitivity by the addition of interferon alpha to chemotherapy was demonstrated in experimental pancreatic cancer for the first time. Since drug-resistance proteins may function as tumor antigens, our data support immunochemotherapy as an encouraging new approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630504

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Impact of Immunotherapy after Resection of Pancreatic Cancer.

Authors:  Thuy B Tran; Vijay K Maker; Ajay V Maker
Journal:  J Am Coll Surg       Date:  2019-02-10       Impact factor: 6.113

2.  Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.

Authors:  Christopher J LaRocca; Joohee Han; Tatyana Gavrikova; Leonard Armstrong; Amanda R Oliveira; Ryan Shanley; Selwyn M Vickers; Masato Yamamoto; Julia Davydova
Journal:  Surgery       Date:  2015-02-27       Impact factor: 3.982

3.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

4.  Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors.

Authors:  Milica Vucetic; Boutaina Daher; Shamir Cassim; Scott Parks; Jacques Pouyssegur
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.

Authors:  Svetlana Karakhanova; Beate Mosl; Sabine Harig; Katharina von Ahn; Jasmin Fritz; Jan Schmidt; Dirk Jäger; Jens Werner; Alexandr V Bazhin
Journal:  Int J Mol Sci       Date:  2014-03-07       Impact factor: 5.923

6.  A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.

Authors:  Angela Märten; Jan Schmidt; Jennifer Ose; Sabine Harig; Ulrich Abel; Marc W Münter; Dirk Jäger; Helmut Friess; Julia Mayerle; Guido Adler; Thomas Seufferlein; Thomas Gress; Roland Schmid; Markus W Büchler
Journal:  BMC Cancer       Date:  2009-05-26       Impact factor: 4.430

7.  Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells.

Authors:  Hongmei Yin; Naifei Chen; Rui Guo; Hong Wang; Wei Li; Guanjun Wang; Jiuwei Cui; Haofan Jin; Ji-Fan Hu
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

8.  Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer.

Authors:  Zibing Wang; Yuqing Liu; Rui'e Li; Yiman Shang; Yong Zhang; Lingdi Zhao; Wei Li; Yonghao Yang; Xiaojie Zhang; Tiejun Yang; Changfu Nie; Feng Han; Ying Liu; Suxia Luo; Quanli Gao; Yongping Song
Journal:  J Hematol Oncol       Date:  2016-02-03       Impact factor: 17.388

9.  Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.

Authors:  Alexandr V Bazhin; Katharina von Ahn; Jasmin Fritz; Jens Werner; Svetlana Karakhanova
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.